{"id":"interferon-2b-ribavirin","safety":{"commonSideEffects":[{"rate":"50-80","effect":"Flu-like symptoms (fever, fatigue, myalgia)"},{"rate":"10-30","effect":"Hematologic toxicity (anemia, leukopenia, thrombocytopenia)"},{"rate":"10-20","effect":"Psychiatric effects (depression, anxiety)"},{"rate":"5-10","effect":"Thyroid dysfunction"},{"rate":"20-40","effect":"Headache"},{"rate":"20-30","effect":"Nausea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Interferon α-2b binds to interferon-α receptors on infected cells, triggering JAK-STAT signaling and upregulation of antiviral genes that inhibit viral protein synthesis and promote apoptosis of infected cells. Ribavirin is a nucleoside analog that inhibits viral RNA-dependent RNA polymerase and depletes cellular guanosine pools, further reducing viral replication. The combination has synergistic antiviral and immunomodulatory effects.","oneSentence":"Interferon α-2b activates innate immunity and has direct antiviral activity, while ribavirin inhibits viral RNA synthesis, together suppressing hepatitis C virus replication.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:49:19.229Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic hepatitis C virus infection"}]},"trialDetails":[{"nctId":"NCT01841775","phase":"PHASE4","title":"Interferon α 2b Pharmacovigilance Study","status":"COMPLETED","sponsor":"The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz)","startDate":"2009-05","conditions":"Hepatitis C, Chronic","enrollment":85},{"nctId":"NCT01457937","phase":"PHASE3","title":"Boceprevir/PegIFN α-2b/Riba in HCV+ Gt1 Menopausal Women, Nonresponders to PegIFN/Riba or Treatment-naives (MEN_BOC)","status":"UNKNOWN","sponsor":"University of Modena and Reggio Emilia","startDate":"2011-11","conditions":"Chronic Hepatitis C, Menopause","enrollment":240}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":25,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"interferon α 2b + ribavirin","genericName":"interferon α 2b + ribavirin","companyName":"The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz)","companyId":"the-immunobiological-technology-institute-bio-manguinhos-oswaldo-cruz-foundation","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Interferon α-2b activates innate immunity and has direct antiviral activity, while ribavirin inhibits viral RNA synthesis, together suppressing hepatitis C virus replication. Used for Chronic hepatitis C virus infection.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}